MCL1 and acute myeloid leukemia: Venetoclax-based regimens have produced high remission rates in older AML patients by ablating the apoptotic blockade, but their durability is limited by resistance mechanisms such as upregulation of alternative anti-apoptotic proteins (MCL-1, BCL-X_L) or metabolic changes in leukemic cells.